Bio‑Techne Corporation reported its second‑quarter fiscal 2026 results on February 4 2026, delivering net sales of $295.9 million—essentially flat year‑over‑year after a $297.03 million sale in Q2 FY2025. GAAP operating margin rose to 18.4 % from 16.0 % a year earlier, while adjusted operating margin climbed to 31.1 %, a 100‑basis‑point gain. Earnings per share beat consensus: GAAP EPS of $0.24 surpassed the $0.22 estimate, and adjusted EPS of $0.46 exceeded the $0.42 consensus by $0.04, a 9.5 % lift.
The revenue flatness was driven by a 4 % decline in the Diagnostics and Spatial Biology segment, offset by a 2 % increase in the Protein Sciences segment. Protein Sciences generated $215.1 million in sales, up 2 % reported but down 1 % organic, reflecting a mix shift toward higher‑margin products. Diagnostics and Spatial Biology posted $81.2 million, down 4 % reported but 3 % organic, as demand from emerging biotech and U.S. academic customers softened due to funding constraints and shifting research priorities.
Margin expansion was largely attributable to the divestiture of Exosome Diagnostics, which removed a lower‑margin business and improved the company’s cost structure. The divestiture also lifted the adjusted gross margin from 70.5 % to 68.5 % year‑over‑year, while the GAAP gross margin improved to 18.4 % from 16.0 %. Cost control initiatives and pricing power in the Protein Sciences segment helped sustain operating leverage even as overall sales remained flat.
Management reiterated its guidance for the remainder of fiscal 2026, maintaining expectations for low‑single‑digit organic revenue growth and a margin expansion target of at least 100 basis points for the full year. The company’s outlook signals confidence in its high‑margin verticals while acknowledging the need to navigate headwinds in emerging biotech and academic markets.
Market reaction was tempered by valuation concerns. Despite the EPS beat and margin gains, investors focused on the flat revenue trajectory and the potential for a slowdown in high‑growth segments. Analysts noted that the company’s strong profitability does not fully offset the lack of top‑line momentum, leading to a cautious stance on future growth prospects.
CEO Kim Kelderman emphasized that “the quarter reflects continued execution in a stabilizing operating environment.” He highlighted robust demand from large pharmaceutical customers and double‑digit growth in China/APAC, while noting tariff uncertainties and NIH budget risks as near‑term headwinds. The comments underscore management’s focus on maintaining profitability while addressing market‑specific challenges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.